• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Acta biomaterialia >Novel borate glass/chitosan composite as a delivery vehicle for teicoplanin in the treatment of chronic osteomyelitis.
【24h】

Novel borate glass/chitosan composite as a delivery vehicle for teicoplanin in the treatment of chronic osteomyelitis.

机译：新型硼酸盐玻璃/壳聚糖复合物作为替考拉宁治疗慢性骨髓炎的递送载体。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Composite materials composed of borate bioactive glass and chitosan (designated BGC) were investigated in vitro and in vivo as a new delivery system for teicoplanin in the treatment of chronic osteomyelitis induced by methicillin-resistant Staphylococcus aureus (MRSA). In vitro, the release of teicoplanin from BGC pellets into phosphate-buffered saline (PBS), as well as its antibacterial activity, were determined. The compressive strength of the pellets was measured after specific immersion times, and the structure of the pellets was characterized using scanning electron microscopy and X-ray diffraction. In vivo, the tibial cavity of New Zealand White rabbits was injected with MRSA strain to induce chronic osteomyelitis, treated by debridement after 4weeks, implanted with teicoplanin-loaded BGC pellets (designated TBGC) or BGC pellets, or injected intravenously with teicoplanin. After 12weeks' implantation, the efficacy of the TBGC pellets for treating osteomyelitis was evaluated using hematological, radiological, microbiological and histological techniques. When immersed in PBS, the TBGC pellets provided a sustained release of teicoplanin, while the surface of the pellets was converted to hydroxyapatite (HA). In vivo, the best therapeutic effect was observed in animals implanted with TBGC pellets, resulting in significantly lower radiological and histological scores, a lower positive rate of MRSA culture, and an excellent bone defect repair, without local or systemic side effects. The results indicate that TBGC pellets are effective in treating chronic osteomyelitis by providing a sustained release of teicoplanin, in addition to participating in bone regeneration.
机译：体外和体内研究了由硼酸盐生物活性玻璃和壳聚糖组成的复合材料（指定为BGC）作为替考拉宁治疗耐甲氧西林金黄色葡萄球菌（MRSA）引起的慢性骨髓炎的新型递送系统。在体外，测定了替考拉宁从BGC药丸中释放到磷酸盐缓冲液（PBS）中的抗菌活性。在特定的浸没时间后测量粒料的抗压强度，并使用扫描电子显微镜和X射线衍射表征粒料的结构。在体内，向新西兰白兔的胫骨腔注射MRSA菌株以诱发慢性骨髓炎，在4周后进行清创术治疗，植入负载替考拉宁的BGC颗粒（指定为TBGC）或BGC颗粒，或静脉注射替考拉宁。植入12周后，使用血液学，放射学，微生物学和组织学技术评估了TBGC颗粒治疗骨髓炎的疗效。当浸入PBS中时，TBGC沉淀可提供替考拉宁的持续释放，而沉淀的表面则转化为羟磷灰石（HA）。在体内，在植入TBGC颗粒的动物中观察到最佳治疗效果，从而导致放射学和组织学评分明显降低，MRSA培养物的阳性率降低以及出色的骨缺损修复，而没有局部或全身性副作用。结果表明，TBGC颗粒通过提供替考拉宁的持续释放以及参与骨骼再生，可有效治疗慢性骨髓炎。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号